Novo Nordisk A/S vs UnitedHealth Group: Business Model & Financial Comparison 2026
Novo Nordisk A/S · Healthcare / Drug Manufacturers - General·UnitedHealth Group · Healthcare / Healthcare Plans
Financial Comparison
| Metric | NVONovo Nordisk A/S | UNHUnitedHealth Group |
|---|---|---|
| Market Cap | $171.96B | $255.31B |
| Revenue (TTM) | $309.06B | $447.57B |
| Revenue Growth | -7.6% | 12.3% |
| Gross Margin | 82.4% | 18.5% |
| Operating Margin | 44.5% | 0.3% |
| Net Margin | 33.1% | 2.7% |
| Return on Equity | 60.7% | 12.5% |
| P/E (Trailing) | 10.8x | 21.2x |
| P/E (Forward) | 11.5x | 14.1x |
| Free Cash Flow | $376.9M | $13.86B |
| Cash | $26.96B | $28.12B |
| Total Debt | $130.96B | $83.00B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
Novo Nordisk A/S
Novo Nordisk A/S stands as a leading company in Healthcare. Generating $309.06 billion in annual revenue (growing -7.6% year-over-year) and carrying a market capitalization of $173.66 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Novo Nordisk A/S continues to execute on a multi-year strategic vision that balances growth inv…
Full Novo Nordisk A/S analysis →UnitedHealth Group
UnitedHealth Group Incorporated stands as a leading company in Healthcare. Generating $447.57 billion in annual revenue (growing 12.3% year-over-year) and carrying a market capitalization of $261.58 billion, the company has cemented its position as a foundational player in the global Healthcare Plans landscape. Under the leadership of its leadership team, UnitedHealth Group Incorporated continues to execute on a multi-year strategic vision that b…
Full UnitedHealth Group analysis →SWOT Analysis Comparison
Strengths
Novo Nordisk A/S
- With a market capitalization of $173.66B, Novo Nordisk A/S is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access tha
- Novo Nordisk A/S's gross margin of 82.4% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 44.5% demonstrates disc
- A return on equity of 60.7% demonstrates that Novo Nordisk A/S generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
UnitedHealth Group
- With a market capitalization of $261.58B, UnitedHealth Group Incorporated is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and cap
- Revenue grew 12.3% year-over-year to $447.57B, indicating strong demand for UnitedHealth Group Incorporated's products and services and outperformance relative to many industry peers.
- UnitedHealth Group Incorporated generated $13.86B in free cash flow, providing financial flexibility to invest in growth initiatives, return capital to shareholders, or strengthen the balance sheet.
Weaknesses
Novo Nordisk A/S
- Novo Nordisk A/S's debt-to-equity ratio of 67.5 indicates meaningful financial leverage. Total debt stands at $130.96B against $26.96B in cash and equivalents.
- Year-over-year revenue declined 7.6%, raising questions about demand for Novo Nordisk A/S's core offerings and requiring management to articulate a credible recovery path.
UnitedHealth Group
- UnitedHealth Group Incorporated's debt-to-equity ratio of 81.6 indicates meaningful financial leverage. Total debt stands at $83.00B against $28.12B in cash and equivalents.
- A net profit margin of 2.7% leaves limited buffer against revenue fluctuations or cost increases. Any significant market downturn could quickly pressure profitability.
- With 390,000 employees globally, UnitedHealth Group Incorporated faces inherent challenges in agility, decision-making speed, and maintaining a consistent culture across geographies — advantages that
Opportunities
Novo Nordisk A/S
- Novo Nordisk A/S operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in thi
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Novo No
- With $26.96B in cash and strong free cash flow generation, Novo Nordisk A/S is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
UnitedHealth Group
- UnitedHealth Group Incorporated operates in the Healthcare Plans segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for UnitedH
- With $28.12B in cash and strong free cash flow generation, UnitedHealth Group Incorporated is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographi
Threats
Novo Nordisk A/S
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Novo Nordisk A/S's revenue is not fully insulated from macroeconomic cycles, and a recession
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Novo Nordisk A/S's
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
UnitedHealth Group
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. UnitedHealth Group Incorporated's revenue is not fully insulated from macroeconomic cycles,
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on UnitedHealth Group
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolNovo Nordisk A/S vs UnitedHealth Group: FAQ
- Is Novo Nordisk A/S bigger than UnitedHealth Group?
- By market capitalization, UnitedHealth Group is larger at $255.31B vs Novo Nordisk A/S's $171.96B.
- Which has better profit margins — Novo Nordisk A/S or UnitedHealth Group?
- Novo Nordisk A/S has higher net profit margins (33.1%) compared to UnitedHealth Group (2.7%). Gross and operating margins are compared in the table above.
- What sectors do Novo Nordisk A/S and UnitedHealth Group operate in?
- Novo Nordisk A/S operates in the Healthcare sector (Drug Manufacturers - General). UnitedHealth Group operates in the Healthcare sector (Healthcare Plans).
- How does Novo Nordisk A/S's revenue compare to UnitedHealth Group's?
- Novo Nordisk A/S generates $309.06B in annual revenue (TTM) while UnitedHealth Group generates $447.57B. UnitedHealth Group is the larger company by revenue as of 2026.